AT
VRTX icon

Arlington Trust’s Vertex Pharmaceuticals VRTX Stock Holding History

Arlington Trust’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$48.2K Sell
97
-4
-4% -$1.77K ﹤0.01% 273
2026
Q1 		$45.1K Buy
101
+89
+742% +$41.5K ﹤0.01% 230
2025
Q4 		$5.44K Sell
12
-259
-96% -$112K ﹤0.01% 373
2025
Q3 		$106K Sell
271
-36
-12% -$15K 0.02% 256
2025
Q2 		$137K Buy
307
+3
+1% +$1.38K 0.03% 222
2025
Q1 		$147K Buy
304
+12
+4% +$5.59K 0.03% 208
2024
Q4 		$118K Hold
292
– – 0.02% 246
2024
Q3 		$136K Hold
292
– – 0.03% 217
2024
Q2 		$137K Buy
292
+233
+395% +$101K 0.03% 205
2024
Q1 		$24.7K Sell
59
-8
-12% -$3.38K 0.01% 320
2023
Q4 		$27.3K Buy
67
+33
+97% +$12.2K 0.01% 327
2023
Q3 		$11.8K Buy
+34
New +$11.9K ﹤0.01% 220

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BHIA
Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return

Arlington Trust's VRTX Position: Q2 2026 in Review

Arlington Trust reduced its Vertex Pharmaceuticals (VRTX) stake by 4% in Q2 2026, selling an estimated $1.77K and leaving 97 shares worth $48.2K. The position accounts for ﹤0.01% of the portfolio, ranked #273.

Arlington Trust first reported a position in VRTX in Q3 2023 and has held it in 12 quarters since. The position peaked at $147K in Q1 2025. 324 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Arlington Trust held 97 shares of Vertex Pharmaceuticals worth $48.2K as of Q2 2026.
  • Arlington Trust sold 4 Vertex Pharmaceuticals shares in Q2 2026, an estimated $1.77K.
  • Vertex Pharmaceuticals made up ﹤0.01% of Arlington Trust's portfolio in Q2 2026, its #273 holding.
  • Arlington Trust first reported a position in Vertex Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
  • Arlington Trust's Vertex Pharmaceuticals position peaked at $147K in Q1 2025.
  • 324 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Arlington Trust's 13F filing for Q2 2026, filed 7 Jul 2026.